<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191447</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0319 - FLAMBOYANT200/12</org_study_id>
    <nct_id>NCT04191447</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Double-dummy, National, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Flamboyant 200/12
      association in adults with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind and double-dummy</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Forced expiratory volume in 1 second (FEV1), obtained through espirometry.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study.</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>FLAMBOYANT 200/12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
1 Flamboyant 200/12 capsule
1 Budesonide/formoterol Placebo capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide/formoterol 400/12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is double-dummy. Thus, the participant must inhale 2 (two) capsules twice a day (12/12h), as follow:
1 Budesonide/formoterol 400/12 capsule
1 Flamboyant 200/12 Placebo capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flamboyant 200/12</intervention_name>
    <description>Flamboyant 200/12 capsule</description>
    <arm_group_label>FLAMBOYANT 200/12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide / Formoterol 400/12</intervention_name>
    <description>Budesonide / Formoterol 400/12 capsule</description>
    <arm_group_label>Budesonide/formoterol 400/12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Flamboyant 200/12 Placebo</intervention_name>
    <description>Flamboyant 200/12 Placebo capsule</description>
    <arm_group_label>Budesonide/formoterol 400/12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Budesonide / Formoterol 400/12 Placebo</intervention_name>
    <description>Budesonide / Formoterol 400/12 Placebo capsule</description>
    <arm_group_label>FLAMBOYANT 200/12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to confirm voluntary participation and agree to all trial purposes by signing
             and dating the informed consent forms;

          -  Participants aged 18 years or more;

          -  Diagnosis of uncontrolled severe asthma;

          -  Participants with Forced expiratory volume in 1 second (FEV1) &gt; 60% of predicted;

        Exclusion Criteria:

          -  Any clinical and laboratory findings that, in the judgment of the investigator, may
             interfere with the safety of research participants;

          -  Known hypersensitivity to the formula components used during the clinical trial;

          -  History of alcohol and/or substance abuse within 12 months prior to Screening Visit.

          -  Current smoking or smoking history equivalent to &quot;10 pack years&quot;

          -  Participants with untreated oral candidiasis;

          -  Pulmonary disease history (e.g., chronic obstructive pulmonary disease [COPD], cystic
             fibrosis, bronchiectasis, tuberculosis);

          -  Participants with a history of acute asthma exacerbation, respiratory tract infection
             or hospitalization for asthma in the last 4 weeks;

          -  Known HIV-positive status or active hepatitis B or C virus test result

          -  Participants with current evidence or history of uncontrolled coronary artery disease,
             congestive heart failure, myocardial infarction or cardiac arrhythmia;

          -  Participants with a current medical history of cancer and/or cancer treatment in the
             last 5 years;

          -  Participants using medications that would have an effect on bronchospasm and / or lung
             function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa FB Oliveira, MD</last_name>
    <phone>+551938879851</phone>
    <email>pesquisa.clinica@ncfarma.com.br</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

